Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Frontiers in Immunology|January 2, 2025
Impact of COVID-19, lockdowns and vaccination on immune responses in a HIV cohort in the NetherlandsTwan Otten, Xun Jiang, Manoj Kumar Gupta, et al.
Brain and Behavior|October 20, 2024
Mental health and its consequences in people living with HIV: A network approachElise M G Meeder, Louise E van Eekeren, Marc J T Blaauw, et al.
Open Forum Infectious Diseases|June 13, 2024
Liver Steatosis is Prevalent in Lean People With HIV and Associated With Exposure to Antiretroviral Treatment-A Cross-sectional StudyLouise E van Eekeren, Nadira Vadaq, Wilhelm A J W Vos, et al.
The Journal of Infection|March 22, 2026
Residual HIV viremia strongly increases cardiovascular disease incidence independent of classical risk factorsTwan Otten, Suzanne D E Ruijten, Marc J T Blaauw, et al.
Science Translational Medicine|May 8, 2020
Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1Johanna M Eberhard, Mathieu Angin, Caroline Passaes, et al.
Ebiomedicine|October 19, 2024
Plasma proteomic signatures of liver steatosis and fibrosis in people living with HIV: a cross-sectional studyLouise E van Eekeren, Quirijn de Mast, Elise M G Meeder, et al.
Frontiers in Immunology|May 23, 2024
HIV immunological non-responders are characterized by extensive immunosenescence and impaired lymphocyte cytokine production capacityWilhelm A J W Vos, Adriana Navas, Elise M G Meeder, et al.
Leukemia & Lymphoma|January 9, 2014
Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patientsBlanca Xicoy, Josep-Maria Ribera, Markus Müller, et al.
AIDS (London, England)|March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAmy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.
The Lancet. Infectious Diseases|February 15, 2014
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trialRichard B Pollard, Jürgen K Rockstroh, Giuseppe Pantaleo, et al.
Pageof 12